NCT00057811 - Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2004

Primary Completion Date

October 31, 2009

Study Completion Date

July 31, 2014

Conditions

Childhood Burkitt LymphomaChildhood Diffuse Large Cell LymphomaChildhood Immunoblastic Large Cell LymphomaStage I Childhood Large Cell LymphomaStage I Childhood Small Noncleaved Cell LymphomaStage II Childhood Large Cell LymphomaStage II Childhood Small Noncleaved Cell LymphomaStage III Childhood Large Cell LymphomaStage III Childhood Small Noncleaved Cell LymphomaStage IV Childhood Large Cell LymphomaStage IV Childhood Small Noncleaved Cell LymphomaUntreated Childhood Acute Lymphoblastic Leukemia

Interventions

DRUG

doxorubicin hydrochloride

Given IV, IT, or orally

DRUG

cyclophosphamide

Given IV

DRUG

methotrexate

Given IV or IT

DRUG

rasburicase

Given IV

DRUG

leucovorin calcium

Given IV or orally

DRUG

prednisone

Given IV or orally

DRUG

methylprednisolone

Given IV or orally

BIOLOGICAL

filgrastim

Given subcutaneously

BIOLOGICAL

rituximab

Given IV

DRUG

cytarabine

Given IT

DRUG

etoposide

Given IV

DRUG

vincristine sulfate

Given IV

DRUG

hydrocortisone sodium succinate

Given IT

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

91006-3776

Children's Oncology Group, Arcadia

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Children's Oncology Group

NETWORK